National
Gay soldier accused of leaking classified files
Did anger over ‘Don’t Ask’ motivate Manning to act?
Reports that a U.S. Army intelligence analyst who’s accused of leaking classified information is gay have raised questions about whether a resentment of “Don’t Ask, Don’t Tell” could have motivated his alleged crime.
Pfc. Bradley Manning, 22, is the prime suspect in the investigation of leaked video footage showing a U.S. Apache helicopter strike in Baghdad that killed 12 civilians, including employees of a Reuters news agency.
Manning allegedly gave the footage to WikiLeaks, a whistle-blowing website devoted to disclosing the secrets of governments and corporations.
In an instant message conversation with a friend, Manning reportedly said he was responsible for the leak as well as another video showing a 2009 Garani air strike in Afghanistan. He also reportedly claimed to have 260,000 classified U.S. diplomatic cables that would reveal the inner workings of U.S. embassies.
“Hillary Clinton, and several thousand diplomats around the world are going to have a heart attack when they wake up one morning, and find an entire repository of classified foreign policy is available, in searchable format, to the public,” Manning said in the conversation, according to Wired.com.
Additionally, Manning is a person of interest in an investigation seeking to determine the source of thousands of secret documents leaked related to the Afghanistan war. But as of earlier this week, Manning reportedly hadn’t been formally named as a suspect in the matter.
The charges against Manning are serious. Lt. Col. Rene White, a Pentagon spokesperson, said Manning is under investigation “for allegedly improperly downloading, storing and disclosing to unauthorized third parties classified or sensitive [U.S. government] documents or media.”
White said Manning is being held in the brig at the U.S. Marine Corps base in Quantico, Va.
“Manning will remain in pre-trial confinement as the Army continues its investigation,” White said. “We don’t know if Pfc. Manning is the source of the recently leaked documents. We are assessing them now to determine the potential damage to lives, sources and methods and national security.”
Courtney Whittmann, a spokesperson for U.S. Army Military District of Washington, said Manning could face up to 52 years in prison and a dishonorable discharge as well as forfeiture of all pay and allowances. She said the court of his appearance is yet to be determined.
As this investigation is underway, a report from British media describing Manning as gay is raising questions about whether discontent with “Don’t Ask, Don’t Tell” contributed to his alleged decision to leak the classified material.
The Daily Telegraph reported that Manning is openly gay and had several postings on his Facebook page that he was unhappy with the military and was going through relationship troubles with a same-sex partner.
At the beginning of May, Manning reportedly wrote he was “livid” after being “lectured by ex-boyfriend,” then later posted that he was “not a piece of equipment” and was “beyond frustrated with people and society at large.”
In the same month, when he was serving at a U.S. military base near Baghdad, Manning reportedly changed his status to: “Bradley Manning is now left with the sinking feeling that he doesn’t have anything left.”
The publicly viewable portion of his Facebook profile this week listed the Washington Blade as among his favorite pages as well as several other LGBT-related pages, including the Human Rights Campaign, gay Rep. Barney Frank (D-Mass.) and “REPEAL THE BAN — End ‘Don’t Ask, Don’t Tell.’”
After Window Media closed the Blade late last year, Manning donated $120 to a “Save the Blade” initiative that helped re-launch the paper, according to Blade records.
Manning has also been seen in gay venues in D.C. and was present at the National Stonewall Democrats’ Capital Champions event in 2009.
Jon Hoadley, a gay activist and former Stonewall Democrats president, is among those who know Manning. Still, Hoadley said he said he didn’t know Manning well and hasn’t seen him in more than a year.
“Other [than] through some Stonewall events and stuff like that — and through a few friends — I didn’t know him really well,” Hoadley said.
Whittmann, the Army military district of Washington spokesperson, said she didn’t immediately know whether “Don’t Ask, Don’t Tell” was a factor in the investigation of Manning, but said she would look to find more information on the matter.
The co-director of OutServe, an organization for LGBT active duty service members, said he was skeptical that “Don’t Ask, Don’t Tell” played a role in Manning’s alleged decision to leak classified information.
OutServe’s co-director, who’s adopted the alias J.D. Smith to avoid being outed under “Don’t Ask, Don’t Tell,” said he didn’t think Manning’s discontent with the law led him to his alleged decision to leak classified information.
“From what I’ve being reading on this situation, he had a lot of issues that he was dealing with — not just about his homosexuality,” said Smith, who noted OutServe has had no contact with Manning. “We don’t know all the factors. All the details haven’t come out to the public yet.”
The Family Research Council has seized on reports that Manning is gay to drum up opposition to repealing “Don’t Ask, Don’t Tell.”
In an e-mail blast, Tony Perkins, president of FRC, called Manning an “extreme homosexual activist” and said his “fury over the services’ homosexual policy may have led him to publicize highly classified documents about the wars.”
“Unfortunately for all of us, Manning’s betrayal painfully confirms what groups like FRC have argued all along: the instability of the homosexual lifestyle is a detriment to military readiness,” Perkins wrote.
John Aravosis, a gay D.C.-based blogger, responded to the FRC mailing on his website, Americablog.com, calling it evidence of the continued lies and distortion that FRC puts forth on LGBT issues.
“FRC cites the Telegraph, and claims that the Telegraph says Manning has an ‘extensive history’ of campaigning for gay rights,” Aravosis wrote. “In fact, the Telegraph article mentions that Manning once showed up at a single gay rights rally — that’s it. How is that an ‘extensive’ history as an ‘extreme’ gay activist? It’s not.”
Aravosis also disputed the notion that evidence exists showing that anger over “Don’t Ask, Don’t Tell” led Manning to leak classified information.
“Finally, there’s nothing, anywhere, to suggest that Manning had any ‘fury’ over [‘Don’t Ask, Don’t Tell’], or that, even if he did, such fury led him to leak the documents,” Aravosis said. “Where did FRC come up with it?”
Smith said FRC’s decision to try to solicit funds over the charges against Manning is “pretty awful.”
“There are plenty of instances where straight soldiers have done things as well,” Smith said. “And I don’t think they should [be] playing this as homosexual treason at all. I think that we need to be very careful in how this is portrayed.”
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Kazakh president signs anti-LGBTQ propaganda bill
Top 10 LGBTQ local news stories of 2025
The 25 greatest queer movies of the 21st century so far
How to cope when a partner gives you the silent treatment
Out actor talks lead role in ‘Fiddler on the Roof’
Your guide to D.C.’s queer New Year’s Eve parties
Holiday week brings setbacks for Trump-Vance trans agenda
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
